AASLD 2020
13-16 November, 2020
Digital edition
ENYO Pharma attended the 2020 digital edition of AASLD meeting.
The meeting confirms vonafexor (EYP001, FXRag) unique positioning for HBV and possible differentiated profile for NASH with ph2s on track to deliver in H1 2021.
We also presented a poster describing a novel small molecule modulating the mitochondrial NEET proteins that improves inflammation and fibrosis in liver and kidneys of NASH mice :
Download the poster (PDF)Read next in 'Events'
- The 2024 international workshop on Alport syndrome
- ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport
- 6th CKD Summit – Chronic Kidney Disease Drug Development
- ASN Kidney Week
- Alport Connect 2023, the annual Alport syndrome patient and family meeting in US